Search the Newsreel

Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Vyne Therapeutics Inc (VYNE), detailing its current price momentum score, support and resistance levels, and indicator readings. It highlights that VYNE is suitable for range-bound swing trading, with several indicators showing "Buy" signals, particularly its moving averages. …

Janus Henderson Group (VYNE) reports 9.99% Yarrow Bioscience stake and pre-funded warrants

Janus Henderson Group Ltd., through its investment adviser subsidiaries, has reported a beneficial ownership of 9.99% in Yarrow Bioscience, Inc. common stock, totaling 266,712 shares held across various managed client accounts. Additionally, the asset managers may beneficially own 1,895,248 pre-funded warrants, which are subject …

OrbiMed discloses sub-10% Yarrow Bioscience, Inc. (Ticker: VYNE) stake and large warrants

OrbiMed-affiliated funds have reported a 9.97% beneficial ownership stake in Yarrow Bioscience, Inc. following its merger with a wholly owned subsidiary of VYNE Therapeutics Inc. The investment firm acquired 266,306 shares and substantial pre-funded warrants to purchase an additional 4,668,372 shares. These warrants are …

OrbiMed Advisors Discloses Investment at Yarrow Bioscience with 9.97% Stake

OrbiMed Advisors LLC has disclosed a 9.97% stake in Yarrow Bioscience, Inc. following Yarrow's merger into VYNE Therapeutics. The investment firm states its purpose is for investment only, not control, and may adjust its position based on market conditions. OrbiMed is a healthcare-focused investment …

Yarrow Bioscience (VYNE) sees 9.9% ownership stake from Logos Global funds

Logos Global Management LP and its related entities have reported a beneficial ownership of up to 9.9% of Yarrow Bioscience (VYNE) common stock, comprising common shares and prefunded warrants, subject to a 9.99% beneficial ownership limitation. The ownership calculation is based on 2,669,788 shares …

VYNE Therapeutics (NASDAQ:VYNE) Sees Large Volume Increase - Here's Why

VYNE Therapeutics (NASDAQ:VYNE) experienced a significant 55% increase in trading volume, with 15,572 shares changing hands, while its stock price slightly decreased by 0.6% to $25.20. Despite beating EPS estimates in its last quarterly report, revenue fell short, and analyst sentiment remains cautious with …

Yarrow Bioscience, Inc. (YARW) director discloses 87,820 option grant from merger

Yarrow Bioscience, Inc. director Peter B. Silverman reported an initial holding of 87,820 stock options to purchase common stock at an exercise price of $6.19 per share, expiring April 17, 2036. These options were received as part of a merger where a subsidiary of …

Yarrow Bioscience, Inc. (VYNE) CEO lists 878,194-share stock option from merger

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) CEO Rebecca Frey has reported beneficial ownership of a stock option to purchase 878,194 shares of common stock at an exercise price of $6.1900 per share, expiring on January 30, 2036. This option was received in connection …

Yarrow Bioscience (VYNE) director lists 87,820-share stock option

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) director William Richard White has reported initial insider holdings of an 87,820-share stock option. This option, with an exercise price of $6.19 per share and expiring on April 17, 2036, was issued following the merger of a …

Yarrow Bioscience (VYNE) reports CDO option holdings

Yarrow Bioscience's Chief Development Officer, Lori Payton, has reported a stock option holding of 175,639 shares of Issuer Common Stock with an exercise price of $6.19. This option, which expires on January 30, 2036, was acquired through a merger where VYNE Therapeutics Inc. changed …

Yarrow Bioscience (VYNE) awards 185,798 stock options to director Tyler

Yarrow Bioscience (VYNE) has awarded 185,798 stock options to director Zeronda Tyler. These options have an exercise price of $28.56 per share and expire on July 27, 2036. The options will vest over four years, with one-quarter vesting on July 27, 2027, and the …

[Form 3] VYNE Therapeutics Inc. Initial Statement of Beneficial Ownership

A recent Form 3 filing indicates that Steven L. Hoerter, a director of Yarrow Bioscience (formerly VYNE Therapeutics Inc.), holds a stock option to purchase 87,820 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on April 17, 2036. …

Yarrow Bioscience (YARW) completes VYNE merger and funds YB-101

Yarrow Bioscience (formerly VYNE Therapeutics) has completed its merger with privately held Yarrow Bioscience, changing its name and ticker to YARW and effecting a 1-for-50 reverse stock split. The combined company secured $200 million in financing, expected to fund operations into 2028, and will …

Debt to equity ratio of VYNE Therapeutics Inc. – NASDAQ:YARW

This article provides the debt to equity ratio for VYNE Therapeutics Inc. (NASDAQ: YARW). The content primarily focuses on the debt to equity ratio, presented as a financial metric within the TradingView platform. No specific value for the ratio is given in the provided …

VYNE Therapeutics Inc. Earnings and Revenue – NASDAQ:YARW

Analysts predict VYNE Therapeutics Inc. (NASDAQ:YARW) will report an earnings per share of -9.00 USD and revenue of 200.00K USD for the upcoming quarter. The company's financial overview, including statements, statistics, dividends, and past earnings, is accessible to investors. This data helps assess the …

VYNE Therapeutics Inc. Cash Flow – NASDAQ:YARW

This article provides details on the cash flow of VYNE Therapeutics Inc. (NASDAQ: YARW). For Q1 2026, the free cash flow was -4.08 million USD. In 2025, the company reported a free cash flow of -33.12 million USD, with operating cash flow also at …

Net income before discontinued operations of VYNE Therapeutics Inc. – NASDAQ:YARW

This article briefly notes the net income before discontinued operations for VYNE Therapeutics Inc. (NASDAQ: YARW). The content provides basic financial information within a TradingView context, displaying the company's NASDAQ stock market details. The short piece does not elaborate on specific figures but confirms …

VYNE Therapeutics Inc. Balance Sheet – NASDAQ:YARW

VYNE Therapeutics Inc.'s Q1 2026 balance sheet shows total assets of $25.87 million USD, marking a 14.21% decrease from Q4 2025. During the same period, total liabilities significantly decreased by 48.39% to $1.24 million USD. The article provides an overview of the company's financial …

Vyne Therapeutics Inc (NASDAQ: VYNE) Share Price, VYNE Stock News, VYNE Share Price & Updates

Yarrow Bioscience Completes VYNE Merger and $200 Million Private Financing

Yarrow Bioscience has completed its merger with VYNE Therapeutics and closed approximately $200 million in private financing, forming a new clinical-stage biotechnology company. The combined entity will trade on Nasdaq under the ticker YARW and will focus on developing treatments for autoimmune thyroid diseases, …

Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Vyne Therapeutics Inc (VYNE), focusing on business segments and regional contributions. As of the latest update, the company has only disclosed royalty revenues amounting to $570.00K, with details for other segments and regional contributions yet to be …

VYNE|Vyne Therapeutics Inc|Price:0.509|Chg%:-0.012

Vyne Therapeutics Inc. (VYNE) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and immune-mediated conditions. The company's lead programs include repibresib gel (VYN201) and VYN202, both BET inhibitors. The article also provides detailed company information, executive shareholdings, and institutional ownership …

Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Vyne Therapeutics Inc.'s (VYNE) dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years. However, it lists several stock split events, all classified as mergers, with varying …

Vyne Therapeutics Inc (VYNE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Vyne Therapeutics Inc (VYNE) Income Statement

This article provides a detailed quarterly and annual income statement for Vyne Therapeutics Inc (VYNE), covering various financial metrics from total revenue to net income and EPS across multiple fiscal periods. It also includes an FAQ section explaining how to interpret the income statement …

VYNE Therapeutics Inc. Revenue Breakdown – NASDAQ:VYNE

The article provides a brief overview of VYNE Therapeutics Inc.'s revenue breakdown, highlighting that its greatest contribution came from the United States. In the last year, the US market accounted for $570,000 USD, down from $501,000 USD the previous year. This information is derived …

VYNE Therapeutics (Ticker: VYNE) CFO reports tax-share withholding event

VYNE Therapeutics Inc.'s Chief Financial Officer, Tyler Zeronda, had 22,516 shares of common stock withheld on July 23, 2026, to cover tax obligations from the vesting of restricted stock units. The shares were valued at $0.8976 each. Following this withholding, Zeronda directly holds 74,918 …

VYNE Therapeutics (VYNE) CLO has shares withheld for RSU taxes

VYNE Therapeutics' Chief Legal Officer, Mutya Harsch, had 22,516 shares of common stock withheld by the company on July 23, 2026. This action, valued at $0.8976 per share, was taken to satisfy tax obligations related to the vesting of restricted stock units. Following this …

Tax withholding trims stake of VYNE Therapeutics Inc. (VYNE) CSO

VYNE Therapeutics Inc.'s Chief Scientific Officer, Stuart Iain, had 15,405 shares of common stock withheld on July 23, 2026, to cover tax obligations related to the vesting of restricted stock units. The shares were valued at $0.8976 each, and following this transaction, Iain now …

VYNE Dividend Distributed as Yarrow Merger Awaits Nasdaq Approval

VYNE Therapeutics has distributed a special cash dividend and is proceeding with a 1-for-50 reverse stock split on July 24, 2026. The proposed merger with Yarrow Bioscience, initially expected around July 24, is now anticipated to close early in the week of July 27, …

VYNE Therapeutics To Go Ex-Dividend On July 24th, 2026 With 0.40242 USD Special Dividend Per Share

VYNE Therapeutics (VYNE) is scheduled to go ex-dividend on July 24th, 2026. Shareholders will receive a special dividend of $0.40242 per share. Investors need to own shares before the ex-dividend date to be eligible for this payment.

VYNE Therapeutics approves 1-for-50 reverse stock split By Investing.com

VYNE Therapeutics Inc. announced its Board of Directors approved a 1-for-50 reverse stock split of its common stock, with shares expected to trade under the new name Yarrow Bioscience, Inc. and ticker YARW on July 27. This decision follows stockholder approval and precedes the …

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

VYNE Therapeutics Inc. has announced a 1-for-50 reverse stock split and provided an update on a special cash dividend, both in preparation for its proposed merger with Yarrow Bioscience, Inc. The reverse split will reduce outstanding shares significantly, and the combined company will trade …